Aducanumab for cognitive dysfunction

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trials ended early. Its trials were stopped early. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 21 Aug 2018: Trial registered, NCT03639987
  2. 20 Dec 2018: Trial started, NCT03639987
  3. 30 Jul 2019: Trial terminated, NCT03639987
  4. 16 Sep 2021: Trial results posted, NCT03639987

The trials

NCT03639987: A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities

State
Stopped early
Phase
Phase 2
People
52 taking part
Started
20 Dec 2018
Primary completion
30 Jul 2019
Arms
Group 2
Results
Posted on the registry
  1. 21 Aug 2018: Trial registered
  2. 20 Dec 2018: Trial started
  3. 30 Jul 2019: Trial terminated
  4. 16 Sep 2021: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Trials ended early

About the treatment

Kind of treatment: Drug.

Also known as Aducanumab (BIIB037).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.